DK3233907T3 - Bispecifikke heterodimeriske proteiner hos gnavere - Google Patents

Bispecifikke heterodimeriske proteiner hos gnavere Download PDF

Info

Publication number
DK3233907T3
DK3233907T3 DK15820114.5T DK15820114T DK3233907T3 DK 3233907 T3 DK3233907 T3 DK 3233907T3 DK 15820114 T DK15820114 T DK 15820114T DK 3233907 T3 DK3233907 T3 DK 3233907T3
Authority
DK
Denmark
Prior art keywords
rodents
heterodimeric proteins
bispecific heterodimeric
bispecific
proteins
Prior art date
Application number
DK15820114.5T
Other languages
English (en)
Inventor
Joyce I Meesters
Janine Schuurman
Paul Parren
Anthony Armstrong
Matthew Bunce
Mark Chiu
Thomas Nesspor
Adam Zwolak
Aran F Labrijn
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Application granted granted Critical
Publication of DK3233907T3 publication Critical patent/DK3233907T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
DK15820114.5T 2014-12-19 2015-12-18 Bispecifikke heterodimeriske proteiner hos gnavere DK3233907T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400744 2014-12-19
PCT/EP2015/080509 WO2016097300A1 (en) 2014-12-19 2015-12-18 Rodent bispecific heterodimeric proteins

Publications (1)

Publication Number Publication Date
DK3233907T3 true DK3233907T3 (da) 2021-06-07

Family

ID=55069840

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15820114.5T DK3233907T3 (da) 2014-12-19 2015-12-18 Bispecifikke heterodimeriske proteiner hos gnavere

Country Status (4)

Country Link
US (1) US10865253B2 (da)
EP (1) EP3233907B1 (da)
DK (1) DK3233907T3 (da)
WO (1) WO2016097300A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
WO2017194592A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of storing a separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
ES2874974T3 (es) 2016-05-11 2021-11-05 Cytiva Bioprocess R & D Ab Matriz de separación
CN109311948B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 清洁和/或消毒分离基质的方法
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
EP3733716A4 (en) * 2017-12-26 2021-11-24 Nanjing GenScript Biotech Co., Ltd. DIMERAL FUSION PROTEIN USING ANTIBODY FC REGION AS A SKELETON AND ASSOCIATED USE
CN112513074A (zh) * 2018-06-22 2021-03-16 健玛保 生产两种或更多种不同抗体的受控混合物的方法
EP3877409A1 (en) 2018-11-06 2021-09-15 Genmab A/S Antibody formulation

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292668A (en) 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0912612B1 (de) 1996-07-25 2003-10-01 GSF - Forschungszentrum für Umwelt und Gesundheit, GmbH Vereinfachte herstellung bispezifischer antikörperfragmente
US20040038894A1 (en) 1996-12-31 2004-02-26 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Compounds for modulating cell negative regulations and biological applications thereof
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
CA2327505A1 (en) 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
DE19859110A1 (de) 1998-09-25 2000-04-13 Horst Lindhofer Bispezifische und trispezifische Antikörper, die spezifisch mit induzierbaren Oberflächenantigenen als operationelle Zielstrukturen reagieren
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
IL159225A0 (en) 2001-06-13 2004-06-01 Genmab As Human monoclonal antibodies to epidermal growth factor receptor (egfr)
PL216630B1 (pl) 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
US7960512B2 (en) * 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20050163782A1 (en) 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
AU2003280713A1 (en) 2003-11-04 2005-05-19 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
EP1697748A4 (en) 2003-12-22 2007-07-04 Centocor Inc METHODS FOR GENERATING MULTIMEDIA MOLECULES
US8772013B2 (en) 2004-02-02 2014-07-08 Engeneic Molecular Delivery Pty Ltd Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
CA2580981C (en) 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Stabilized human igg4 antibodies
EP1805320B1 (en) 2004-10-22 2014-09-03 Amgen Inc. Methods for refolding of recombinant antibodies
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
KR20080104343A (ko) 2006-03-03 2008-12-02 엘란 파마슈티칼스, 인크. 나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
JP5570974B2 (ja) 2007-05-31 2014-08-13 ゲンマブ エー／エス 一価ヒト抗体を産生するトランスジェニック動物およびこれらの動物から得ることのできる抗体
US20100267934A1 (en) 2007-05-31 2010-10-21 Genmab A/S Stable igg4 antibodies
DK2235064T3 (da) * 2008-01-07 2016-01-11 Amgen Inc Fremgangsmåde til fremstilling af Fc-heterodimeriske molekyler under anvendelse af elektrostatiske styringseffekter
US7951370B2 (en) 2008-03-12 2011-05-31 Imclone Llc Anti-TYRP1 antibodies
ES2458541T3 (es) 2008-05-02 2014-05-06 Seattle Genetics, Inc. Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
SG10201610247QA (en) 2008-12-03 2017-02-27 Genmab As Antibody variants having modifications in the constant region
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR101930964B1 (ko) 2010-04-20 2018-12-19 젠맵 에이/에스 이종이량체 항체 ｆｃ-함유 단백질 및 그의 생산 방법
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
DK2635607T3 (da) 2010-11-05 2019-11-18 Zymeworks Inc Stabilt heterodimert antistofdesign med mutationer i fc-domænet
WO2012116453A1 (en) 2011-03-03 2012-09-07 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
US20140170148A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2
US20140170149A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CN104114579B (zh) 2011-10-27 2020-01-24 健玛保 异二聚体蛋白的生成
EA031184B1 (ru) 2012-11-21 2018-11-30 Янссен Байотек, Инк. БИСПЕЦИФИЧЕСКИЕ К EGFR/c-Met АНТИТЕЛА
SG10201803449VA (en) * 2013-09-27 2018-05-30 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer

Also Published As

Publication number Publication date
EP3233907B1 (en) 2021-03-03
WO2016097300A1 (en) 2016-06-23
US10865253B2 (en) 2020-12-15
US20170327597A1 (en) 2017-11-16
EP3233907A1 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
CL2018000370A1 (es) Nuevos anticuerpos anti-pd-1
DK3233907T3 (da) Bispecifikke heterodimeriske proteiner hos gnavere
DK3292141T3 (da) Fusionsproteiner
DK3180363T3 (da) Sirp-alpha-immunoglobulin fusionsproteiner
DK3197453T3 (da) Kimært protein
DK3344654T3 (da) Anti-lag-3-antistoffer
BR112017001385A2 (pt) anticorpos anti-pd-1
DK4089113T3 (da) Polypeptider
DK3195160T3 (da) Computerstyret doseringssystem
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
DK3107562T3 (da) P97-ids-fusionsproteiner
DK3143037T3 (da) Alpha4beta7-integrin-thioether-peptidantagonister
ES2965032T3 (es) Fabricación de proteínas
DK3145946T3 (da) Bakteriebaseret proteintilførsel
DK3041857T3 (da) Protein a-kromatografi
DK3180315T3 (da) Pyrazoler
DK3250593T3 (da) Anti-transthyretin-antistoffer
DK3215530T3 (da) Forbedrede il-6 antistoffer
DK3362578T3 (da) Fremgangsmåder til genomvurdering hos husdyr
DK3099791T3 (da) Protein
DK3398449T3 (da) Fremgangsmåde til smoltificering hos salmonidae
DK3380168T3 (da) Injektionsanordning
DK3355967T3 (da) Injektionsapparat
DK3099793T3 (da) Protein
DK3132031T3 (da) Carbohydratbindende protein